1. Home
  2. MHH vs ACRV Comparison

MHH vs ACRV Comparison

Compare MHH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mastech Digital Inc

MHH

Mastech Digital Inc

HOLD

Current Price

$6.79

Market Cap

76.3M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.72

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHH
ACRV
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.3M
74.0M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
MHH
ACRV
Price
$6.79
$1.72
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
★ $12.75
$11.50
AVG Volume (30 Days)
6.1K
★ 209.9K
Earning Date
10-30-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 15.13
EPS
★ 0.01
N/A
Revenue
★ $191,371,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.86
N/A
P/E Ratio
$634.00
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.50
$1.27
52 Week High
$8.37
$3.56

Technical Indicators

Market Signals
Indicator
MHH
ACRV
Relative Strength Index (RSI) 36.21 40.93
Support Level $6.24 $1.63
Resistance Level $6.80 $2.21
Average True Range (ATR) 0.33 0.10
MACD 0.00 -0.01
Stochastic Oscillator 20.20 27.69

Price Performance

Historical Comparison
MHH
ACRV

About MHH Mastech Digital Inc

Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: